These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 33811295)

  • 1. An Abductive Inference Approach to Assess the Performance-Enhancing Effects of Drugs Included on the World Anti-Doping Agency Prohibited List.
    Breenfeldt Andersen A; Jacobson GA; Bejder J; Premilovac D; Richards SM; Rasmussen JJ; Jessen S; Hostrup M
    Sports Med; 2021 Jul; 51(7):1353-1376. PubMed ID: 33811295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultra high performance liquid chromatography tandem mass spectrometry determination and profiling of prohibited steroids in human biological matrices. A review.
    Gosetti F; Mazzucco E; Gennaro MC; Marengo E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 927():22-36. PubMed ID: 23317577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and Development of the List of Prohibited Substances and Methods.
    Kinahan A; Budgett R; Mazzoni I
    Med Sport Sci; 2017; 62():39-54. PubMed ID: 28571027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Australian athletes' knowledge of the WADA Prohibited Substances List and performance enhancing substances.
    Orr R; Grassmayr M; Macniven R; Grunseit A; Halaki M; Bauman A
    Int J Drug Policy; 2018 Jun; 56():40-45. PubMed ID: 29550541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Can furosemide mask the use of performance-enhancing drugs?].
    Brinkman DJ; Tichelaar J; Van Agtmael MA
    Ned Tijdschr Geneeskd; 2021 May; 165():. PubMed ID: 34346634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects.
    Heuberger JAAC; Cohen AF
    Sports Med; 2019 Apr; 49(4):525-539. PubMed ID: 30411235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Pain Killers on the Urinary Anabolic Steroid Profile.
    Stoll A; Iannone M; De Gregorio G; de la Torre X; Molaioni F; Botrè F; Kristina Parr M
    J Anal Toxicol; 2020 Dec; 44(8):871-879. PubMed ID: 32390041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doping substances in dietary supplements.
    Helle C; Sommer AK; Syversen PV; Lauritzen F
    Tidsskr Nor Laegeforen; 2019 Feb; 139(4):. PubMed ID: 30808106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating the use of stimulants in out-of-competition sport samples.
    Boghosian T; Mazzoni I; Barroso O; Rabin O
    J Anal Toxicol; 2011 Nov; 35(9):613-6. PubMed ID: 22080900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The list of prohibited substances and methods in sport: structure and review process by the world anti-doping agency.
    Mazzoni I; Barroso O; Rabin O
    J Anal Toxicol; 2011 Nov; 35(9):608-12. PubMed ID: 22080899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anabolic and lipolytic actions of beta
    Hostrup M; Jacobson GA; Jessen S; Lemminger AK
    Drug Test Anal; 2020 May; 12(5):597-609. PubMed ID: 31960603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone abuse in sports: the antidoping perspective.
    Barroso O; Mazzoni I; Rabin O
    Asian J Androl; 2008 May; 10(3):391-402. PubMed ID: 18385901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase Type 5 Inhibitors, Sport and Doping.
    Di Luigi L; Sansone M; Sansone A; Ceci R; Duranti G; Borrione P; Crescioli C; Sgrò P; Sabatini S
    Curr Sports Med Rep; 2017; 16(6):443-447. PubMed ID: 29135645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An (un)desirable trade of harms? How elite athletes might react to medically supervised 'doping' and their considerations of side-effects in this situation.
    Overbye M
    Int J Drug Policy; 2018 May; 55():14-30. PubMed ID: 29477956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pheromones: a new ergogenic aid in sport?
    Papaloucas M; Kyriazi K; Kouloulias V
    Int J Sports Physiol Perform; 2015 Oct; 10(7):939-40. PubMed ID: 25710097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance-enhancing drugs: understanding the risks.
    Hatton CK; Green GA; Ambrose PJ
    Phys Med Rehabil Clin N Am; 2014 Nov; 25(4):897-913. PubMed ID: 25442165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Athlete Biological Passport: an integral element of innovative strategies in antidoping.
    Vernec AR
    Br J Sports Med; 2014 May; 48(10):817-9. PubMed ID: 24659508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doping and musculoskeletal system: short-term and long-lasting effects of doping agents.
    Nikolopoulos DD; Spiliopoulou C; Theocharis SE
    Fundam Clin Pharmacol; 2011 Oct; 25(5):535-63. PubMed ID: 21039821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen- and estrogen-receptor mediated activities of 4-hydroxytestosterone, 4-hydroxyandrostenedione and their human metabolites in yeast based assays.
    Keiler AM; Zierau O; Wolf S; Diel P; Schänzer W; Vollmer G; Machalz D; Wolber G; Parr MK
    Toxicol Lett; 2018 Aug; 292():39-45. PubMed ID: 29702199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The World Anti-Doping Code 2003--consequences for physicians associated with elite athletes.
    Striegel H; Rössner D; Simon P; Niess AM
    Int J Sports Med; 2005 Apr; 26(3):238-43. PubMed ID: 15776342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.